Longeveron (NASDAQ:LGVN) stock continues to rally on Thursday as investors celebrate positive trial news from the clinical-stage biotechnology company.
The big news that boosted shares of LGVN stock higher was investigator data from a Phase 2 trial of Lomocel-B. This is the company’s treatment candidate for patients suffering from hypoplastic left heart syndrome (HLHS).
The Phase 2 trial of Lomocel-B is still ongoing and the investigator meeting was positive. That’s a win for the company and investors in LGVN stock. There’s also demand for its product as HLHS is often fatal and requires many surgeries.
https://investorplace.com/2024/06/why-is-longeveron-lgvn-stock-up-46-today/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.